RAAS blockade and SGLT2 inhibitors are both associated with significant renal hemodynamic mediated dips in GFR, which may limit their use in patients with renal function at lower limits of clinical trial inclusion criteria (≤30 mL/min in the CREDENCE trial or ≤25 mL/min in the DAPA-CKD trial). The gene discussed is SLC5A2; the disease is chronic kidney disease.